Literature DB >> 30668309

Paraneoplastic hyperbilirubinemia in metastatic prostate cancer and review of the current literature.

Pınar Gökçen1, Kaan Gökçen2, Erol Çakmak1, Gökhan Gökçe2.   

Abstract

Paraneoplastic syndromes are functional clinical disorders caused by the direct effect of the primary tumor or metastasis. The initial presenting symptom of the patients may be associated with paraneoplastic manifestations. Paraneoplastic cholestasis is most frequently defined in association with renal cell carcinoma (Stauffer's syndrome), but it is an extremely rare clinical entity seen in association with prostate cancer. Etiology of cholestasis was investigated in the case diagnosed as metastatic prostate cancer who applied to the gastroenterology outpatient clinic due to complaints of ascites and jaundice that established the diagnosis of paraneoplastic hyperbilirubinemia. We observed improvement of his cholestasis with hormonotherapy used for prostate cancer.

Entities:  

Year:  2018        PMID: 30668309      PMCID: PMC6342570          DOI: 10.5152/tud.2018.52059

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  9 in total

1.  Paraneoplastic hepatic dysfunction in metastatic prostate cancer: the role of cytokine dysregulation.

Authors:  Vi Nguyen; Howard Gurney; David van der Poorten
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

2.  Idiopathic cholestatic jaundice may be a paraneoplastic manifestation of underlying malignancy: a case of prostate cancer.

Authors:  Akihiro Okano; Masaya Ohana; Fusako Kusumi
Journal:  Clin J Gastroenterol       Date:  2014-04-12

Review 3.  Inflammation-induced cholestasis.

Authors:  M Trauner; P Fickert; R E Stauber
Journal:  J Gastroenterol Hepatol       Date:  1999-10       Impact factor: 4.029

4.  Intermittent cholestatic jaundice and nonmetastatic prostatic carcinoma.

Authors:  A N Reddy; S J Grosberg; S Wapnick
Journal:  Arch Intern Med       Date:  1977-11

Review 5.  Paraneoplastic syndromes in prostate cancer.

Authors:  Matthew K Hong; Jennifer Kong; Benjamin Namdarian; Anthony Longano; Jeremy Grummet; Christopher M Hovens; Anthony J Costello; Niall M Corcoran
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

6.  Characterization of the role of IL-6 in the progression of prostate cancer.

Authors:  T D Chung; J J Yu; M T Spiotto; M Bartkowski; J W Simons
Journal:  Prostate       Date:  1999-02-15       Impact factor: 4.104

7.  Paraneoplastic cholestasis associated with prostate carcinoma.

Authors:  Mehmet Koruk; Mehmet Büyükberber; Cemil Savaş; Abdurrahman Kadayifçi
Journal:  Turk J Gastroenterol       Date:  2004-03       Impact factor: 1.852

8.  [Stauffer's syndrome disclosing kidney cancer: another cause of inflammatory syndrome with anicteric cholestasis].

Authors:  H Gil; B de Wazières; H Desmurs; T Fest; J L Dupond
Journal:  Rev Med Interne       Date:  1995       Impact factor: 0.728

9.  Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma.

Authors:  S P Dourakis; C Sinani; M Deutsch; E Dimitriadou; S J Hadziyannis
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-03       Impact factor: 2.566

  9 in total
  1 in total

1.  Severe Cholestatic Jaundice (Stauffer Syndrome) as a Rare Paraneoplastic Manifestation in Adrenocortical Carcinoma.

Authors:  Natia Murvelashvili; Patricio M Polanco; Sarah M Khorsand; Jorge A Marrero; Liwei Jia; Sasan Mirfakhraee; Tobias Else; Mouhammed Amir Habra; Suzanne Cole; Oksana Hamidi
Journal:  J Endocr Soc       Date:  2022-06-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.